The Risk of Lymph Node Metastasis in Gastric Cancer Conforming to Indications of Endoscopic Resection and Pylorus-preserving Gastrectomy: a Single-center Retrospective Study
Overview
Affiliations
Background: Lymph node metastasis (LNM) status is an important prognostic factor that strongly influences the treatment decision of early gastric cancer (EGC). This study aimed to evaluate the pattern and clinical significance of LNM in EGC.
Methods: A total of 354 patients with carcinoma in situ (n = 42), EGC (n = 312) who underwent radical gastrectomy were enrolled. Their clinicopathological features, pathological reports, and prognostic data were collected and analyzed.
Results: The incidence of LNM in all patients was 18.36% (65/354). The rates of D1 and D2 station metastases were 12.10% (43/354) and 6.21% (22/354), respectively. The rates of LNM in absolute indication of endoscopic resection and expanded indication were 3.27% (2/61) and 28.55% (4/14), respectively. Skip LNM was observed in 3.67% (13/354) of patients. For those with middle-third tumor, the metastasis rate of the No. 5 lymph node was 3.05% (5/164). The independent risk factors for LNM were tumors measuring > 30 mm, poorly differentiated tumors, and lymphovascular invasion (all P < 0.05; area under the curve, 0.783). The 5-year disease-free survival rates of patients with and without LNM were 96.26 and 79.17%, respectively (P = 0.011). Tumors measuring > 20 mm and LNM were independent predictive factors for poor survival outcome in all patients.
Conclusions: Patients with EGC conforming to expanded indications have a relatively high risk of LNM and may not be suitable for endoscopic submucosal dissection. Pylorus-preserving gastrectomy for patients with middle-third EGC remains controversial due to the high metastasis rate of the No. 5 lymph node.
Nie G, Geng L, Zhang H, Chu S, Jiang H Front Med (Lausanne). 2025; 12:1492041.
PMID: 40070650 PMC: 11893835. DOI: 10.3389/fmed.2025.1492041.
Endoscopic Resection of Early Gastric Cancer and Pre-Malignant Gastric Lesions.
Vasconcelos A, Dinis-Ribeiro M, Libanio D Cancers (Basel). 2023; 15(12).
PMID: 37370695 PMC: 10296667. DOI: 10.3390/cancers15123084.
Hou S, Liu F, Gao Z, Ye Y World J Surg Oncol. 2022; 20(1):308.
PMID: 36153587 PMC: 9508780. DOI: 10.1186/s12957-022-02766-0.
Deng C, Zhang Z, Qi H, Guo Z, Liu Y, Xiao H Front Oncol. 2022; 12:917541.
PMID: 36052237 PMC: 9425773. DOI: 10.3389/fonc.2022.917541.
Gheran C, Voicu S, Galateanu B, Callewaert M, Moreau J, Cadiou C Int J Mol Sci. 2022; 23(6).
PMID: 35328678 PMC: 8955704. DOI: 10.3390/ijms23063258.